Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Temperature-controlled shipping is equally vital, as exposure to heat during transit can degrade the peptide, compromising its potency and potentially requiring dosage adjustments
This approach requires discipline and a solid lifestyle foundation, but it is financially more sustainable for many people
SURPASS-4, a multicenter open-label RCT comparing treatment with tirzepatide and insulin glargine in T2D patients at increased CV risk for a median of 85 weeks, was the only study in the SURPASS program to include the change from baseline in eGFR and UACR and occurrence of eGFR decline of at least 40%, renal death, progression to end-stage kidney disease or new-onset MA among the prespecified analyses [48]
Tirzepatide currently leads in head-to-head comparisons against semaglutide for diabetes management
